Hemay-102

N/A

Report date: 2024/11/21 20:00:04
NME

Base Information

Drug NameHemay-102
Drug Alias NameHemay-102
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA-directed DNA polymerase inhibitorsTopoisomerase II inhibitors
TargetsDNA-directed DNA polymeraseTopoisomerase II
Therapy Area/IndicationsSolid tumoursLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesTianjin Hemay Bio-Tech Co LtdHainan Hailing Chemipharma Corporation Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesTianjin Hemay Bio-Tech Co LtdTianjin Hemay Oncology Pharmaceutical Co LtdHainan Hailing Chemipharma Corporation Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A